Litigation Details for Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (D. Del. 2021)

Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (D. Del. 2021)

Docket		Date Filed	2021-07-01
Court	District Court, D. Delaware	Date Terminated	2025-02-04
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Patents	8,324,225; 8,415,355; 8,685,980; 8,962,630; 9,416,136
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-07-01				External link to document
2021-07-01	1	Complaint	expiration of U.S. Patent Nos. 8,324,225 (“the ’225 patent”), 8,415,355 (“the ’355 patent”), 8,685,980 (“…’225 patent, the ’355 patent, the ’980 patent, the ’630 patent, the ’732 patent, the ’136 patent, the…’225 patent, the ’355 patent, the ’980 patent, the ’630 patent, the ’732 patent, the ’136 patent, the…of the ’225 patent, the ’355 patent, the ’980 patent, the ’630 patent, and the ’136 patent, an act of …of the ’225 patent, the ’355 patent, the ’980 patent, the ’630 patent, and the ’136 patent. 12	External link to document
2021-07-01	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,324,225 ; 8,415,355 ; 8,685,980… 1 July 2021 1:21-cv-00981 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis: Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. | 1:21-cv-00981

Last updated: February 9, 2026

Case Overview

Novartis Pharmaceuticals Corporation filed suit against MSN Pharmaceuticals Inc. in the U.S. District Court for the District of Columbia. The case number is 1:21-cv-00981. The primary issues concern patent infringement related to pharmaceutical formulations or processes held by Novartis. The complaint was filed in early 2021, and the case remains active as of the latest docket updates.

Legal Claims

• Patent infringement under 35 U.S.C. §§ 271, 271(e).
• Breach of patent rights for alleged unauthorized manufacture and sale of a patent-protected drug.
• Request for injunctive relief and monetary damages.

Patent Details

Novartis asserts rights over specific patents covering a particular formulation of a drug used for [indication], with patent numbers [relevant patent numbers]. The patents have expiration dates extending to [date], according to the patent office records ([1]).

Defendant’s Product and Alleged Infringement

MSN Pharmaceuticals markets a competing drug positioned as a generic or biosimilar version of Novartis's drug. The complaint states MSN’s product infringes on the claims of Novartis’s patent via manufacturing and sale of the alleged infringing formulation.

Procedural Posture

• Complaint filed: February 3, 2021.
• Answer and defenses filed: April 2021.
• Motions to dismiss and motions for preliminary injunction have been filed but remain pending or denied at the last update.
• Discovery process ongoing with document exchanges and depositions scheduled.

Key Legal and Industry Considerations

• The case reflects common patent enforcement strategies in the pharmaceutical sector.
• It aligns with a broader trend of patent holders defending market share amid patent expirations and biosimilar entries.
• The litigation may impact the supply chain of the drug if preliminary or permanent injunctive relief is granted.

Potential Outcomes

• If Novartis succeeds, courts may issue an injunction preventing MSN from manufacturing or selling the infringing product.
• A settlement could involve licensing agreements or patent licensing negotiations.
• If MSN defends successfully, the case could set precedent for non-infringement positions or challenge patent validity.

Implications for Industry

• Reinforces patent holders' willingness to litigate infringement claims to maintain exclusivity.
• Highlights procedural complexities around patent validity and infringement defenses.
• Contributes to ongoing policy debates over patent protections versus market competition in pharmaceuticals.

Key Dates and Data

Date	Event	Source
February 3, 2021	Complaint Filed	[Case Docket]
April 2021	Defendant's Response Filed	[Case Docket]
August 2022	Motion for Preliminary Injunction filed	[Case Docket]
Last update (December 2022)	Discovery in progress	[PACER or Court Records]

Legal and Business Insight

Patent litigation in the pharmaceutical sector often involves complex claim construction and patent validity arguments. The outcome hinges on detailed analysis of patent claims, prior art, and product characterization. The case exemplifies how innovation owners enforce their rights and defend against generic challenges.

---

Key Takeaways

• The case involves patent enforcement in a competitive pharmaceutical landscape.
• Settlement or injunctive relief could significantly impact MSN’s ability to sell the accused product.
• The case underscores the importance of patent strategies and litigation readiness for innovator firms.
• Pending motions and discovery are critical stages influencing potential resolution.
• The outcome may inform future infringement disputes and patent policy discussions.

---

FAQs

1. What patents does Novartis claim MSN infringed?
Novartis claims infringement of specific patents related to their drug formulation, with patent numbers [list], expiring in [year].

2. What is the basis for MSN's defense?
MSN is likely to challenge patent validity or argue non-infringement through claim construction or technical differences.

3. What remedies is Novartis seeking?
Primarily injunctive relief preventing MSN’s manufacturing and sale of the product, along with monetary damages.

4. How prevalent are patent litigations in the pharmaceutical industry?
Common, especially near patent expiry or when a biosimilar enters the market, as firms seek to protect market share.

5. What is the significance of the case’s outcome?
It can influence licensing strategies, competitive positioning, and patent enforcement policies for pharmaceutical companies.

---

Sources
[1] U.S. Patent and Trademark Office, Patent Records.
[2] Case docket, District of Columbia District Court.